Contraindications and unsuitable groups for Serputinib/Serpatinib (Ruitu)

Selpercatinib, as a RET receptor tyrosine kinase inhibitor, has shown significant efficacy in the treatment of RET-driven non-small cell lung cancer (NSCLC) and medullary thyroid cancer (thyroid cancer), but it is not suitable for all patients. According to current medical guidelines, there are some contraindications and inapplicable groups for seputinib, which mainly include the following categories:

1. Patients allergic to seputinib ingredients: If patients have allergic reactions to seputinib or any of its ingredients, such as rash, shortness of breath or other allergic symptoms, they should avoid using this drug.

2. Pregnant and lactating women: As Seputinib may have adverse effects on the fetus and infant, pregnant and lactating women should not use this drug. It is not known whether the drug is passed to the baby through breast milk, so its use needs to be avoided during pregnancy and breastfeeding unless the doctor determines that the potential benefits of the drug outweigh the risks.

3. Patients with severe liver dysfunction: The metabolism of seputinib mainly depends on the liver. Therefore, patients with severely impaired liver function (such as patients with cirrhosis or severe liver disease) may not be able to effectively metabolize the drug, resulting in increased blood drug concentration and increased risk of adverse reactions. Therefore, the use of seputinib should be avoided in patients with severe hepatic impairment.

4. Patients with negative RET mutation test results: Seputinib is designed for RET-driven tumors and, therefore, is limited to patients with RET mutation or fusion-positive tumors. Using this drug in patients who are RET mutation-negative has little effect and may increase the risk of side effects.

5. Patients with a history of severe heart disease: Seputinib may have a certain impact on heart function. Caution is required when used in patients with a history of heart disease, especially those with a history of QT prolongation or heart failure.

Therefore, before starting to use seputinib, patients need to undergo RET mutation testing and liver function evaluation to ensure that the drug is suitable for their treatment needs. The use of drugs must be guided and monitored by professional doctors to ensure the safety and effectiveness of treatment.

Reference materials:https://retevmo.lilly.com/how-it-works